Liu B, Zhou T, Geng J, Zhang F, Wang J, Li Y
Department of Interventional Medicine, The Second Hospital of Shandong University, Shandong, Shandong Province, PR of, China.
Indian J Cancer. 2015 Dec;52 Suppl 2:e69-74. doi: 10.4103/0019-509X.172517.
To examine the safety and clinical efficacy of computed tomography (CT)-guided radioactive iodine-125 (125I) seeds implantation for patients with unresectable pancreatic cancer.
A group of 26 patients with pathologically confirmed unresectable pancreatic cancer underwent percutaneous CT-guided 125I seeds implantation. Part of them received transarterial chemotherapy and/or percutaneous transhepatic cholangial drainage before or after seeds implantation. The primary endpoints were the objective response rates, local control rates, and overall survival.
CT scan 2 months after treatment revealed complete response (CR) in 8 patients, partial response (PR) in 9 patients. Overall response rate (CR + PR) is 65.38%. Local control rate was 88.46%. Median survival of the whole group was 15.3 months, whereas for Stage III and IV was 17.6 and 9.1 months, respectively. The estimated 1-year survival was 30.77%.
We consider CT-guided 125I seeds implantation as a safe, effective, uncomplicated treatment for unresectable pancreatic cancer.
探讨计算机断层扫描（CT）引导下放射性碘-125（¹²⁵I）粒子植入术治疗不可切除胰腺癌患者的安全性及临床疗效。
对26例经病理证实为不可切除胰腺癌的患者进行经皮CT引导下¹²⁵I粒子植入术。部分患者在粒子植入术前或术后接受了经动脉化疗和/或经皮经肝胆道引流术。主要终点指标为客观缓解率、局部控制率和总生存期。
治疗后2个月的CT扫描显示，8例患者达到完全缓解（CR），9例患者达到部分缓解（PR）。总缓解率（CR + PR）为65.38%。局部控制率为88.46%。全组患者的中位生存期为15.3个月，而Ⅲ期和Ⅳ期患者的中位生存期分别为17.6个月和9.1个月。估计1年生存率为30.77%。
我们认为CT引导下¹²⁵I粒子植入术是一种安全、有效、简便的不可切除胰腺癌治疗方法。
